Investor Presentaiton
COMPANY OVERVIEW
Building a foundation for growth
2015-2017
Among first to be awarded
cannabis licenses in the
Florida and Texas markets
Began building out
vertically integrated
operations and retail
footprint, launched delivery
service in Florida
SURTERRA
WELLNESS
2018
Beau Wrigley led $65
million Series C round and
became Chairman of the
Board and CEO, assuming
day-to-day control
Executed global
partnership with Jimmy
Buffett to launch Coral
Reefer brand
*Coral Reefer
Expanded retail footprint to
18 stores in Florida at
year-end
2019-2020
Entered third and fourth
markets with acquisitions of
Las Vegas-based vertical
operator, The Apothecary
Shoppe as well as NETA,
the market leader in
Massachusetts, and
Molecular Infusions (nka
Parallel Biosciences), a
leading cannabis-focused
R&D innovator:
THE
APOTHECARY
NE
A
SHOPPE
Mi
MOLECULAR
INFUSIONS
Partnered with leading
Company completed Series
D round, raising $125+
million for M&A and
strategic growth initiatives
Rebranded corporate entity
as Parallel, uniting business
under one global identity:
Parallel
Further increased Florida
store footprint to reach
79% of state population
within a 30-minute drive
Launched new brand, float,
targeting the mass-market
biopharmaceutical research float
firm Intrexon for next-gen
propagation technology
and rare cannabinoid
commercialization
intrexon
Partnered with UPMC and
was awarded Chapter 20
license in Pennsylvania to
research medical cannabis
and operate six
dispensaries
2021+1
Completed $75 million Series
E round for strategic initiatives
and general corporate
purposes
Merging with Ceres
Acquisition Corp. and expect
to enter the public equity
markets²
C
CERES
Entering into additional
markets via acquisition,
wholesale distribution, or
awarded license (NJ, GA, etc.)
Launching rare cannabinoid
products and beverages using
proprietary emulsion
technology and next-gen
non-THC CBN sleep aid
1. See "Forward-Looking Statements" disclaimer on pages 3-4 and financial assumptions on pages 57-58. 2. Assumes closing of the Transaction with Ceres, which is subject to a number of conditions, including regulatory and securityholder approvals.
27
שייView entire presentation